CN115073583A - 识别hla-cw8限制性突变kras的t细胞受体 - Google Patents

识别hla-cw8限制性突变kras的t细胞受体 Download PDF

Info

Publication number
CN115073583A
CN115073583A CN202111083392.9A CN202111083392A CN115073583A CN 115073583 A CN115073583 A CN 115073583A CN 202111083392 A CN202111083392 A CN 202111083392A CN 115073583 A CN115073583 A CN 115073583A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111083392.9A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·特兰
卢勇成
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN115073583A publication Critical patent/CN115073583A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CN202111083392.9A 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体 Pending CN115073583A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras
CN201680058891.3A CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680058891.3A Division CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Publications (1)

Publication Number Publication Date
CN115073583A true CN115073583A (zh) 2022-09-20

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680058891.3A Active CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体
CN202111083392.9A Pending CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680058891.3A Active CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Country Status (13)

Country Link
US (3) US10556940B2 (enExample)
EP (2) EP3901169A1 (enExample)
JP (2) JP7185524B2 (enExample)
KR (2) KR20250117744A (enExample)
CN (2) CN108350059B (enExample)
AU (3) AU2016323017B2 (enExample)
DK (1) DK3350213T3 (enExample)
ES (1) ES2879287T3 (enExample)
IL (1) IL257840B2 (enExample)
MX (1) MX2018003062A (enExample)
SA (1) SA518391109B1 (enExample)
SG (1) SG10201913868XA (enExample)
WO (1) WO2017048593A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
IL264425B2 (en) 2016-08-02 2023-09-01 Us Secretary Department Of Health And Human Services t cell receptors against kras-g20
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP4234576A3 (en) * 2017-03-31 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
CR20240019A (es) * 2017-09-20 2024-02-15 Us Health RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)
EP4269595A3 (en) 2017-10-05 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selectively expanding cells expressing a tcr with a murine constant region
JP7385566B2 (ja) 2017-12-04 2023-11-22 アメリカ合衆国 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
MX2020014243A (es) * 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CA3109232A1 (en) 2018-08-16 2020-02-20 Biontech Us Inc. T cell receptor constructs and uses thereof
US12448428B2 (en) 2019-01-22 2025-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted t cell receptors against RAS with G12R mutation
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
WO2021029046A1 (ja) * 2019-08-14 2021-02-18 日本電気株式会社 情報処理装置、情報処理方法及び記録媒体
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
MX2022009825A (es) * 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
US20230257440A1 (en) * 2020-07-16 2023-08-17 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037455A1 (en) * 2002-05-30 2005-02-17 Kolesnick Richard N. Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CA2968399A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037455A1 (en) * 2002-05-30 2005-02-17 Kolesnick Richard N. Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREDERICK D. TSAI ET AL.: "K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif", PNAS, vol. 112, no. 3, 20 January 2015 (2015-01-20), pages 779 - 784, XP055314164, DOI: 10.1073/pnas.1412811112 *

Also Published As

Publication number Publication date
EP3350213B1 (en) 2021-03-31
EP3350213A1 (en) 2018-07-25
IL257840B1 (en) 2023-06-01
AU2022209229A1 (en) 2022-09-15
JP7185524B2 (ja) 2022-12-07
EP3901169A1 (en) 2021-10-27
US10556940B2 (en) 2020-02-11
AU2016323017B2 (en) 2020-11-12
JP7461445B2 (ja) 2024-04-03
IL257840B2 (en) 2023-10-01
ES2879287T3 (es) 2021-11-22
CN108350059B (zh) 2021-10-08
CA2998869A1 (en) 2017-03-23
HK1257902A1 (en) 2019-11-01
AU2022209229B2 (en) 2024-05-23
SA518391109B1 (ar) 2022-02-14
US20230406904A1 (en) 2023-12-21
SG10201913868XA (en) 2020-03-30
JP2018535647A (ja) 2018-12-06
AU2021200833A1 (en) 2021-03-04
KR102841067B1 (ko) 2025-08-01
KR20250117744A (ko) 2025-08-05
KR20180044428A (ko) 2018-05-02
US20190040111A1 (en) 2019-02-07
AU2021200833B2 (en) 2022-04-28
US20200148739A1 (en) 2020-05-14
JP2023025108A (ja) 2023-02-21
IL257840A (en) 2018-04-30
MX2018003062A (es) 2018-09-11
US11667692B2 (en) 2023-06-06
CN108350059A (zh) 2018-07-31
DK3350213T3 (da) 2021-06-21
WO2017048593A1 (en) 2017-03-23
AU2016323017A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US11352410B2 (en) Anti-KK-LC-1 T cell receptors
KR102527052B1 (ko) 항-kras-g12d t 세포 수용체
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
WO2024097637A1 (en) Hla-a3-restricted t cell receptors against braf with v600e mutation
WO2022177961A1 (en) Hla class i–restricted t cell receptors against cd22
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination